CD-19 expression stays as eligibility criteria for cell therapy MSAC has rejected a proposal to amend the eligibility criteria for tisagenlecleucel (TIS) (Kymriah) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Novartis had applied for removal of the requirement for patients to test positive for CD-19 expression on their B-cells in ...
News in brief: CAR-T cell eligibility to stay as is; Will haematology patients respond to COVID19 vaccine? Palliative care workforce crisis
15 Mar 2021